China's National Medical Products Administration held an expanded bureau meeting
and announced regulatory steps to speed commercialization and tighten safety
oversight. The NMPA ordered a shift to a prevention‑oriented regulatory model
with deeper risk consultations and expanded social co‑governance to curb safety
risks in key areas. It will establish a service-plus-review-and-approval
mechanism to accelerate R&D translation, explicitly supporting high‑quality
generics and strengthening drug access for special populations while expanding
high‑level external openness. The agency also directed upgrades to regulatory
capacity — implementing plans, enhancing technical supervision, accelerating
talent development and smart regulation — and launched a Clean Drug Regulation
rectification to strengthen oversight and accountability.
